• Canbud Distribution (CBDX) has announced plans to change its name to Steep Hill Inc. and its stock symbol to STPH
  • Once approved, the company will formally announce the name change and the expected effective date of trading under the new name and symbol
  • Canbud Distribution Corporation (CBDX) is a science and technology health and wellness company
  • Canbud Distribution Corporation (CBDX) is unchanged, trading at C$0.035 per share at 2:15 pm EST

Canbud Distribution (CBDX) has announced plans to change its name to Steep Hill Inc. and its stock symbol to STPH.

The proposed changes are subject to approval from the Canadian Securities Exchange and its receipt of new CUSIP and ISIN numbers.

Assuming the satisfaction of these requirements, the company will formally announce the name change and the expected effective date of trading under the new name and symbol.

Sameet Kanade, Chief Executive Officer of the Company, commented on the planned changes.

“The “Steep Hill” name is one of the longest standing brands in the North American analytical testing market within the cannabis sector. Following the closing of the company’s acquisition of US-based, Steep Hill Inc., the focus is on continuing growth in the North American market. The proposed corporate name change is aimed to provide the company with a stronger and more specific brand identity.”

Canbud Distribution Corporation (CBDX) is a science and technology health and wellness company that encompasses plant-based, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoids (CBD) verticals.

Canbud Distribution Corporation (CBDX) is unchanged, trading at C$0.035 per share at 2:15 pm EST.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.